Alpha Cognition Inc. Common Stock (ACOG) es una empresa que cotiza en bolsa en el Servicios Financieros sector, operando dentro de la Financial - Conglomerates industria. La empresa tiene su sede en Vancouver, BC, Canada. El CEO actual es Michael E. McFadden.
ACOG tiene fecha de IPO 2024-11-12, 5 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $102.82M.
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
